Effective prevention of healthcare-associated VRE infections begins with active surveillance programs that facilitate timely interventions to decrease the spread of VRE. Cepheid's Xpert®vanA/vanB delivers on-demand results in less than an hour, reducing the window for potential transmissions from days to minutes. Rapid intervention can prevent VRE transmissions - improving patient care and reducing costs for healthcare facilities.
VRE: A growing concern
The European Antimicrobial Resistance Surveillance System indicates that infection rates with vancomycin-resistant enterococci (VRE) are increasing, particularly in countries with high MRSA prevalence.
- The proportion of invasive vancomycin resistant E. faecium isolates reached 37% in Greece, 33% in Ireland, 29% in Portugal, 21% in the UK and 15% in Germany
- The percentage of invasive vancomycin resistant E. faecalis was found to be more than 6% in Greece and more than 2% in Portugal, Ireland and the UK
CDC, SHEA and WHO have put forward the following guidelines on how to reduce VRE infections:
- Comprehensive surveillance for targeted Multi-Drug Resistant Organisms; especially for those at high risk
- Judicious use of antibiotics
- Application of infection control precautions during patient care
- Education and training of healthcare personnel
- Environmental cleanliness
- Decolonization therapy when appropriate
Important healthcare benefits of rapid screening:
- Allows for an immediate identification of VRE carriers from non-carriers
- Rapid implementation of barrier precaution
- Early identification improves patient bed management
- Cepheid - The Molecular Diagnostics Leader
- Catalog #: GXVANA/B-CE-10
Number of Tests: 10
- How can I place an order?
Submit your request using our Request Information form, or call 1.888.838.3222, select option 1.